Nicotine Pouch Use in Teens Linked to Lower Risk for Continued Vaping
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, May 19, 2025 -- Nicotine pouch use in adolescence is associated with a lower likelihood of continued vaping, according to a study published online May 19 in Pediatrics.
Alyssa F. Harlow, Ph.D., M.P.H., from the University of Southern California in Los Angeles, and colleagues used data from six semiannual waves of a prospective cohort of Southern California adolescents from 2021 to 2024 to examine whether oral nicotine product (ONP) use is associated with vaping behaviors. Data were included for participants who used electronic cigarettes in the past six months at waves 1 to 5 (703 individuals; mean age, 16 years). Associations between ONP use at waves 1 to 5 and subsequent vaping persistence and frequency six months later at waves 2 to 6 were examined.
There were 277 observations of any past six-month ONP use across a total of 1,173 observations (23.7 percent). The researchers found that the likelihood of subsequent vaping persistence was lower in association with past six-month use (versus nonuse) of any ONP, nicotine pouches, and other ONPs (risk ratios, 0.75, 0.43, and 0.72, respectively). There was also an inverse association seen for use of nicotine pouches with past 30-day vaping frequency at follow-up (incidence rate ratio, 0.43). Only inverse associations of nicotine pouch use with vaping persistence remained in a secondary analysis examining ONP use in the past 30 days and restricted to youth reporting past 30-day e-cigarette use at exposure waves.
"We provide initial evidence that youth ONP use may not contribute to increased vaping," the authors write. "Future studies should continue to monitor the impact of ONP use on youth tobacco use behaviors, including their potential to appeal to tobacco-naïve youth and whether they may serve as a substitute (or complement) to concurrent tobacco use behaviors."
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-20 12:00
Read more

- Sexual Assault Triples Suicide Risk Among Veterans
- Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
- FDA Grants Accelerated Approval to Emrelis (telisotuzumab vedotin-tllv) for Non-Small Cell Lung Cancer With High c-Met Protein Overexpression
- Patients Mainly Prefer AI as Second Reader for Screening Mammogram
- U.S. Births Barely Rise in 2024
- FDA Grants Accelerated Approval to Avmapki Fakzynja Co-Pack (avutometinib capsules/defactinib tablets) for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions